+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Gynaecology Drugs Market Report 2023-2033

  • PDF Icon

    Report

  • 340 Pages
  • February 2023
  • Region: Global
  • Vision2Data
  • ID: 5806046
The Gynaecology Drugs Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing development and approval of new drugs

High prevalence of gynecological diseases have urged number of companies to conduct extensive R&D activities for novel therapies. These new approvals help to enhance a competitive environment for novel therapies and thus drive market adoption. For instance, in Dec 2022, FDA approved Brexafemme manufactured by Scynexis for decreasing the recurrence of vulvovaginal candidiasis (RVVC) or chronic yeast infections. In Nov 2022, ELAHERE, manufactured by ImmunoGen, received FDA approval that is used in adults for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, and primary peritoneal cancer treatment.

What Questions Should You Ask before Buying a Market Research Report?

  • How is the Gynaecology Drugs market evolving?
  • What is driving and restraining the Gynaecology Drugs market?
  • How will each Gynaecology Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
  • How will the market shares for each Gynaecology Drugs submarket develop from 2023 to 2033?
  • What will be the main driver for the overall market from 2023 to 2033?
  • Will leading Gynaecology Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
  • How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
  • Who are the leading players and what are their prospects over the forecast period?
  • What are the Gynaecology Drugs projects for these leading companies?
  • How will the industry evolve during the period between 2023 and 2033? What are the implications of Gynaecology Drugs projects taking place now and over the next 10 years?
  • Is there a greater need for product commercialisation to further scale the Gynaecology Drugs market?
  • Where is the Gynaecology Drugs market heading and how can you ensure you are at the forefront of the market?
  • What are the best investment options for new product and service lines?
  • What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Gynaecology Drugs market today, and over the next 10 years:

  • Our 340-page report provides 166 tables and 293 charts/graphs exclusively to you.
  • The report highlights key lucrative areas in the industry so you can target them - NOW.
  • It contains in-depth analysis of global, regional and national sales and growth.
  • It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Gynaecology Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects

  • In addition to revenue forecasting to 2033, the new study provides you with recent results, growth rates, and market shares.
  • You will find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Gynaecology Drugs prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Disease

  • Gynaecology Cancers
  • Contraception
  • Female Infertility
  • Menopausal Disorder
  • Polycystic Ovary Syndrome
  • Gynaecology Infections
  • Endometriosis
  • Other Diseases

Therapeutics

  • Non-hormonal Therapies
  • Anti-Infective Agents
  • Antineoplastic Agents
  • Anti-inflammatory Agents
  • Other Non-hormonal Therapies
  • Hormonal Therapies
  • Estrogen Therapy
  • Progestin Therapy
  • Combination Therapy
  • Thyroid Replacement Therapy
  • Parathyroid Hormone Therapy
  • Other Hormonal Therapies

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Type

  • Generics
  • Branded
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Mexico
  • Rest of Latin America

MEA

  • GCC
  • South Africa
  • Rest of MEA
The report also includes profiles and for some of the leading companies in the Gynaecology Drugs Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer Pharmaceuticals
  • Eli Lilly and Company
  • GSK
  • Janssen Pharma (Part of Johnson & Johnson)
  • Merck
  • Pfizer
  • Roche
Overall world revenue for Gynaecology Drugs Market, 2023 to 2033 in terms of value the market will surpass US$43,561 million in 2023, this work calculates. We predict strong revenue growth through to 2033. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Gynaecology Drugs Market, 2023 to 2033 report help you?

In summary, this 340+ page report provides you with the following knowledge:
  • Revenue forecasts to 2033 for Gynaecology Drugs Market, 2023 to 2033, with forecasts for disease, therapeutics, distribution channel, and type, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
  • Revenue forecasts to 2033 for five regional and 20 key national markets - See forecasts for the Gynaecology Drugs Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
  • Prospects for established firms and those seeking to enter the market - including company profiles for 10 of the major companies involved in the Gynaecology Drugs Market, 2023 to 2033.
Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Gynaecology Drugs Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

Table of Contents

1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Gynaecology Drugs Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered By This Analytical Report Include:
1.6 Who is This Report For?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About
2 Executive Summary
2.1 Geographical Snapshot: Global Gynaecology Drugs Market
2.2 Disease Segment: Market Attractiveness Index
2.3 Therapeutics Segment: Market Attractiveness Index
2.4 Distribution Channel Segment: Market Attractiveness Index
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.2 Market Restraining Factors
3.2.3 Market Opportunities
3.2.4 Challenges
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Supplier Power
3.4.2 Buyer Power
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
4 Global Gynaecology Drugs Market Analysis by Disease
4.1 Key Findings
4.2 Disease Segment Growth Prospects
4.3 Global Gynaecology Drugs Market Size Estimation and Forecast by Disease
4.4 Gynaecology Cancers
4.4.1 Gynaecology Cancers Market Forecast by Region, 2023-2033 (US$ Mn)
4.4.2 Gynaecology Cancers Market Share by Region, 2023-2033 (%)
4.5 Contraception
4.5.1 Contraception Market Forecast by Region, 2023-2033 (US$ Mn)
4.5.2 Contraception Market Share by Region, 2023-2033 (%)
4.6 Female Infertility
4.6.1 Female Infertility Market Forecast by Region, 2023-2033 (US$ Mn)
4.6.2 Female Infertility Market Share by Region, 2023-2033 (%)
4.7 Menopausal Disorders
4.7.1 Menopausal Disorders Market Forecast by Region, 2023-2033 (US$ Mn)
4.7.2 Menopausal Disorders Market Share by Region, 2023-2033 (%)
4.8 Polycystic Ovary Syndrome
4.8.1 Polycystic Ovary Syndrome Market Forecast by Region, 2023-2033 (US$ Mn)
4.8.2 Polycystic Ovary Syndrome Market Share by Region, 2023-2033 (%)
4.9 Gynaecology Infections
4.9.1 Gynaecology Infections Market Forecast by Region, 2023-2033 (US$ Mn)
4.9.2 Gynaecology Infections Market Share by Region, 2023-2033 (%)
4.10 Endometriosis
4.10.1 Endometriosis Market Forecast by Region, 2023-2033 (US$ Mn)
4.10.2 Endometriosis Market Share by Region, 2023-2033 (%)
4.11 Other diseases
4.11.1 Other Diseases Market Forecast by Region, 2023-2033 (US$ Mn)
4.11.2 Other Disease Market Share by Region, 2023-2033 (%)
5 Global Gynaecology Drugs Market Analysis by Therapeutics
5.1 Key Findings
5.2 Therapeutics Segment Growth Prospects
5.3 Global Gynaecology Drugs Market Size Estimation and Forecast by Therapeutics
5.4 Global Gynaecology Drugs Market Share by Therapeutics, 2023 & 2033
5.5 Non-hormonal Therapies
5.5.1 Non-hormonal therapies Market Forecast by Region, 2023-2033 (US$ Mn)
5.5.2 Non-hormonal therapies Market Share by Region, 2023-2033 (%)
5.5.3 Non-hormonal therapies Market Forecast by Type, 2023-2033 (US$ Mn)
5.5.4 Non-hormonal therapies Market Share by Type, 2023-2033 (%)
5.5.4.1 Anti-Infective Agents
5.5.4.4 Antineoplastic Agents
5.5.4.7 Anti-inflammatory Agents
5.5.4.10 Other Non-hormonal Therapies
5.6 Hormonal Therapies
5.6.1 Hormonal Therapies Market Forecast by Region, 2023-2033 (US$ Mn)
5.6.2 Hormonal Therapies Market Share by Region, 2023-2033 (%)
5.6.3 Hormonal Therapies Market Forecast by Type, 2023-2033 (US$ Mn)
5.6.4 Hormonal Therapies Market Share by Type, 2023-2033 (%)
5.6.4.1 Estrogen Therapy
5.6.4.4 Progestin Therapy
5.6.4.7 Combination Therapy
5.6.4.10 Thyroid Replacement Therapy
5.6.4.13 Parathyroid Hormone Therapy
5.6.4.16 Other Hormonal Therapies
6 Global Gynaecology Drugs Market Analysis by Distribution Channel
6.1 Key Findings
6.2 Distribution Channel Segment Growth Prospects
6.3 Global Gynaecology Drugs Market Size Estimation and Forecast by Distribution Channel
6.4 Global Gynaecology Drugs Market Share by Distribution Channel, 2023 & 2033
6.5 Hospital Pharmacies
6.5.1 Hospital Pharmacies Market Forecast by Region, 2023-2033 (US$ Mn)
6.5.2 Hospital Pharmacies Market Share by Region, 2023-2033 (%)
6.6 Retail Pharmacies
6.6.1 Retail Pharmacies Market Forecast by Region, 2023-2033 (US$ Mn)
6.6.2 Retail Pharmacies Market Share by Region, 2023-2033 (%)
6.7 Online Pharmacies
6.7.1 Online Pharmacies Market Forecast by Region, 2023-2033 (US$ Mn)
6.7.2 Online Pharmacies Market Share by Region, 2023-2033 (%)
7 Global Gynaecology Drugs Market Analysis by Generics/Branded
7.1 Key Findings
7.2 Segment Growth Prospects, By Type
7.3 Global Gynaecology Drugs Market Share by Generics/Branded, 2023 & 2033
7.3.1 Gynaecology Drugs Market, By Generics
7.3.1.1 Generic Drugs Market Size Estimation and Forecast
7.3.2 Gynaecology Drugs Market, By Branded
7.3.2.1 Branded Drugs Market Size Estimation and Forecast
8 Global Gynaecology Drugs Market Analysis by Region
8.1 Key Findings
8.2 Regional Market Size Estimation and Forecast
8.3 COVID-19 Impact Analysis: Recovery Scenarios (V, U, W, L)
9 North America Gynaecology Drugs Market Analysis
9.1 Key Findings
9.2 North America Gynaecology Drugs Market Attractiveness Index
9.3 North America Gynaecology Drugs Market by Country, 2023, 2028 & 2033 (US$ Mn)
9.4 North America Gynaecology Drugs Market Size Estimation and Forecast by Country
9.5 North America Gynaecology Drugs Market Size Estimation and Forecast by Disease
9.6 North America Gynaecology Drugs Market Size Estimation and Forecast by Therapeutics
9.7 North America Non-hormonal therapies Market Size Estimation and Forecast by Type
9.8 North America Hormonal Therapies Market Size Estimation and Forecast by Type
9.9 North America Gynaecology Drugs Market Size Estimation and Forecast by Distribution Channel
9.10 U.S.
9.10.1 U.S. Gynaecology Drugs Market by Disease
9.10.2 U.S. Gynaecology Drugs Market by Therapeutics
9.11 Canada
9.11.1 Canada Gynaecology Drugs Market by Disease
9.11.2 Canada Gynaecology Drugs Market by Therapeutics
10 Europe Gynaecology Drugs Market Analysis
10.1 Key Findings
10.2 Europe Gynaecology Drugs Market Attractiveness Index
10.3 Europe Gynaecology Drugs Market by Country, 2023, 2028 & 2033 (US$ Mn)
10.4 Europe Gynaecology Drugs Market Size Estimation and Forecast by Country
10.5 Europe Gynaecology Drugs Market Size Estimation and Forecast by Disease
10.6 Europe Gynaecology Drugs Market Size Estimation and Forecast by Therapeutics
10.7 Europe Non-hormonal therapies Market Size Estimation and Forecast by Type
10.8 Europe Hormonal Therapies Market Size Estimation and Forecast by Type
10.9 Europe Gynaecology Drugs Market Size Estimation and Forecast by Distribution Channel
10.10 Germany
10.10.1 Germany Gynaecology Drugs Market by Disease
10.10.2 Germany Gynaecology Drugs Market by Therapeutics
10.11 U.K.
10.11.1 U.K. Gynaecology Drugs Market by Disease
10.11.2 U.K. Gynaecology Drugs Market by Therapeutics
10.12 France
10.12.1 France Gynaecology Drugs Market by Disease
10.12.2 France Gynaecology Drugs Market by Therapeutics
10.13 Italy
10.13.1 Italy Gynaecology Drugs Market by Disease
10.13.2 Italy Gynaecology Drugs Market by Therapeutics
10.14 Spain
10.14.1 Spain Gynaecology Drugs Market by Disease
10.14.2 Spain Gynaecology Drugs Market by Therapeutics
10.15 Rest of Europe
10.15.1 Rest of Europe Gynaecology Drugs Market by Disease
10.15.2 Rest of Europe Gynaecology Drugs Market by Therapeutics
11 Asia Pacific Gynaecology Drugs Market Analysis
11.1 Key Findings
11.2 Asia Pacific Gynaecology Drugs Market Attractiveness Index
11.3 Asia Pacific Gynaecology Drugs Market by Country, 2023, 2028 & 2033 (US$ Mn)
11.4 Asia Pacific Gynaecology Drugs Market Size Estimation and Forecast by Country
11.5 Asia Pacific Gynaecology Drugs Market Size Estimation and Forecast by Disease
11.6 Asia-Pacific Gynaecology Drugs Market Size Estimation and Forecast by Therapeutics
11.7 Asia-Pacific Non-hormonal therapies Market Size Estimation and Forecast by Type
11.8 Asia-Pacific Hormonal Therapies Market Size Estimation and Forecast by Type
11.9 Asia Pacific Gynaecology Drugs Market Size Estimation and Forecast by Distribution Channel
11.10 Japan
11.10.1 Japan Gynaecology Drugs Market by Disease
11.10.2 Japan Gynaecology Drugs Market by Therapeutics
11.11 China
11.11.1 China Gynaecology Drugs Market by Disease
11.11.2 China Gynaecology Drugs Market by Therapeutics
11.12 India
11.12.1 India Gynaecology Drugs Market by Disease
11.12.2 India Gynaecology Drugs Market by Therapeutics
11.13 South Korea
11.13.1 South Korea Gynaecology Drugs Market by Disease
11.13.2 South Korea Gynaecology Drugs Market by Therapeutics
11.14 Australia
11.14.1 Australia Gynaecology Drugs Market by Disease
11.14.2 Australia Gynaecology Drugs Market by Therapeutics
11.15 Rest of APAC
11.15.1 Rest of APAC Gynaecology Drugs Market by Disease
11.15.2 Rest of APAC Gynaecology Drugs Market by Therapeutics
12 Latin America Gynaecology Drugs Market Analysis
12.1 Key Findings
12.2 Latin America Gynaecology Drugs Market Attractiveness Index
12.3 Latin America Gynaecology Drugs Market by Country, 2023, 2028 & 2033 (US$ Mn)
12.4 Latin America Gynaecology Drugs Market Size Estimation and Forecast by Country
12.5 Latin America Gynaecology Drugs Market Size Estimation and Forecast by Disease
12.6 Latin America Gynaecology Drugs Market Size Estimation and Forecast by Therapeutics
12.7 Latin America Non-hormonal therapies Market Size Estimation and Forecast by Type
12.8 Latin America Hormonal Therapies Market Size Estimation and Forecast by Type
12.9 Latin America Gynaecology Drugs Market Size Estimation and Forecast by Distribution Channel
12.10 Brazil
12.10.1 Brazil Gynaecology Drugs Market by Disease
12.10.2 Brazil Gynaecology Drugs Market by Therapeutics
12.11 Mexico
12.11.1 Mexico Gynaecology Drugs Market by Disease
12.11.2 Mexico Gynaecology Drugs Market by Therapeutics
12.12 Rest of Latin America
12.12.1 Rest of LATAM Gynaecology Drugs Market by Disease
12.12.2 Rest of LATAM Gynaecology Drugs Market by Therapeutics
13 MEA Gynaecology Drugs Market Analysis
13.1 Key Findings
13.2 MEA Gynaecology Drugs Market Attractiveness Index
13.3 MEA Gynaecology Drugs Market by Country, 2023, 2028 & 2033 (US$ Mn)
13.4 MEA Gynaecology Drugs Market Size Estimation and Forecast by Country
13.5 MEA Gynaecology Drugs Market Size Estimation and Forecast by Disease
13.6 MEA Gynaecology Drugs Market Size Estimation and Forecast by Therapeutics
13.7 MEA Non-hormonal therapies Market Size Estimation and Forecast by Type
13.8 MEA Hormonal Therapies Market Size Estimation and Forecast by Type
13.9 MEA Gynaecology Drugs Market Size Estimation and Forecast by Distribution Channel
13.10 South Africa
13.10.1 South Africa Gynaecology Drugs Market by Disease
13.10.2 South Africa Gynaecology Drugs Market by Therapeutics
13.11 GCC
13.11.1 GCC Gynaecology Drugs Market by Disease
13.11.2 GCC Gynaecology Drugs Market by Therapeutics
13.12 Rest of MEA
13.12.1 Rest of MEA Gynaecology Drugs Market by Disease
13.12.2 Rest of MEA Gynaecology Drugs Market by Therapeutics
14 Competitive Landscape
14.1 Company Share Analysis
14.2 Key Business Strategy Analysis
15 Company Profiles
15.1 Pfizer
15.1.1 Company Snapshot
15.1.2 Company Overview
15.1.3 Financial Analysis
15.1.4 Product Benchmarking
15.1.5 Strategic Outlook
15.2 Merck
15.2.1 Company Snapshot
15.2.2 Company Overview
15.2.3 Financial Analysis
15.2.4 Product Benchmarking
15.2.5 Strategic Outlook
15.3 GSK
15.3.1 Company Snapshot
15.3.2 Company Overview
15.3.3 Financial Analysis
15.3.4 Product Benchmarking
15.3.5 Strategic Outlook
15.4 AbbVie
15.4.1 Company Snapshot
15.4.2 Company Overview
15.4.3 Financial Analysis
15.4.4 Product Benchmarking
15.4.5 Strategic Outlook
15.5 Roche
15.5.1 Company Snapshot
15.5.2 Company Overview
15.5.3 Financial Analysis
15.5.4 Product Benchmarking
15.5.5 Strategic Outlook
15.6 Bayer Pharmaceuticals
15.6.1 Company Snapshot
15.6.2 Company Overview
15.6.3 Financial Analysis
15.6.4 Product Benchmarking
15.6.5 Strategic Outlook
15.7 Eli Lilly and Company
15.7.1 Company Snapshot
15.7.2 Company Overview
15.7.3 Financial Analysis
15.7.4 Product Benchmarking
15.7.5 Strategic Outlook
15.8 Janssen Pharma (subsidiary of Johnson and Johnson)
15.8.1 Company Snapshot
15.8.2 Company Overview
15.8.3 Financial Analysis
15.8.4 Product Benchmarking
15.8.5 Strategic Outlook
15.9 AstraZeneca
15.9.1 Company Snapshot
15.9.2 Company Overview
15.9.3 Financial Analysis
15.9.4 Product Benchmarking
15.9.5 Strategic Outlook
15.10 Amgen
15.10.1 Company Snapshot
15.10.2 Company Overview
15.10.3 Financial Analysis
15.10.4 Product Benchmarking
15.10.5 Strategic Outlook
16 Conclusion and Recommendations
16.1 Final findings of report
16.2 Recommendations for Market Players

Companies Mentioned

  • AbbVie
  • Amgen
  • AstraZeneca
  • Bayer Pharmaceuticals
  • Eli Lilly and Company
  • GSK
  • Janssen Pharma (Part of Johnson & Johnson)
  • Merck
  • Pfizer
  • Roche
  • Alkem
  • Astellas Pharma
  • ChemoCentryx, Inc.
  • Daré Bioscience, Inc.
  • Emcure
  • Ferring Pharmaceuticals
  • ImmunoGen
  • Lupin Pharmaceuticals
  • Mankind Pharma
  • Mithra Pharmaceuticals
  • Myovant Sciences
  • Neurocrine Biosciences, Inc.
  • SCYNEXIS
  • European Medicines Agency (EMA)
  • European Pharmaceutical Market Research Association (EPhMRA)
  • Food and Drug Administration (FDA) [US]
  • Health Canada
  • National Development and Reform Commission (NDRC) [China]
  • National Health Services (NHS) [UK]
  • National Institute for Health and Care Excellence (NICE) [UK]
  • National Institute of Allergy and Infectious Diseases (NIAID) [US]
  • National Institutes of Health [US]
  • National Pharmaceutical Pricing Authority (NPPA) [China]
  • Pharmaceuticals and Medical Devices Agency (PMDA) [Japan]
  • Servicio Sanitario Nazionale (SSN) [US]
  • UK Medicines and Healthcare Products Regulatory Agency (MHRA)
  • United States District Court for the District of New Jersey
  • University of California, San Diego [US]
  • University of Michigan [US]
  • US Patent Office